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Abstract
AIMS: In Spain, the first line treatment of hyperphosphatemia in Chronic Kidney Disease (CKD) consists of calcium-
based phosphate binders (CB). However, their use is associated with vascular calcification and an increased mortality
risk. The aim of this study was to assess the incremental cost-effectiveness of second-line Lanthanum Carbonate
(LC) treatment in patients not responding to CB (calcium carbonate and calcium acetate).
Material and methods: A lifetime Markov model was developed considering three health states (predialysis,
dialysis and death). Transitions between states and efficacy data were obtained from randomized clinical trials and
the European Dialysis and Transplant Association Annual report. Mortality rate was adjusted with the relative risk
related to serum phosphorus levels.
According to the Spanish healthcare system perspective, only medical direct costs were considered. Dialysis costs (2013
prices in Euros) were obtained from diagnosis-related groups. Drug costs were derived from ex-factory prices, adjusted
with 7.5% mandatory rebate. Quality of life estimates were based on a published systematic review. Costs and benefits
were discounted at 3%. Deterministic and probabilistic sensitivity analyses (PSA) were conducted.
Results: At the end of simulation, costs per patient with LC therapy were €1,169 and €5,044 with CB alone. 4.653
Quality Adjusted Life Years (QALYs) were gained per patient treated with LC, and 4.579 QALYs with CB. CB therapy
is dominated by the LC strategy (i.e. lower costs, higher QALYs). Assuming a €30,000/QALY threshold, LC was dominant
in 100% of PSA simulations.
Conclusions: LC is a cost-effective second line treatment of hyperphosphatemia in CKD patients irrespective of
dialysis status in Spain.
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Background
Chronic kidney disease (CKD) causes changes in calcium
and phosphorus metabolism leading on hyperphosphate-
mia and hypercalcemia. During the last decade it has been
demonstrated that elevated serum phosphorus (SP) and
calcium levels may cause extraskeletal calcification of the
tunica media in the vasculature of CKD patients [1]. These
calcifications ultimately result in cardiovascular disease
which is the leading cause of morbidity and mortality in
patients with CKD [2].
Treatment guidelines from the Kidney Disease Outcomes
Quality Initiative (K/DOQI) recommend that serum target
levels be maintained between 3.5 and 5.5 mg/dL [3]. How-
ever. Spanish treatment guidelines recommend that SP be
maintained under 4.5 mg/dL [4] and suggest to start the
treatment for hyperphosphatemia, based in calcium-based
phosphate binders (CB) (Calcium carbonate and calcium
acetate), when dietary restrictions are insufficient [4]. How-
ever, it has been demonstrated that treatment with CB
along with decreased of renal excretory capacity in CKD
patients may accelerate the vascular calcification and in-
crease cardiovascular mortality in the long term due to the* Correspondence: ioyaguez@porib.com
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calcium accumulation and/or the continuous hypercalce-
mia [5].
Second line treatment, after therapy failure with CB
treatment, is based on the use of non-calcium binders
including Lanthanum carbonate (LC). The efficacy of
non-calcium binders has been demonstrated, resulting
in the prevention and delay of CKD [6-9].
The cost-effectiveness of LC versus non-calcium
binders for hyperphosphatemia in dialyzed patients has
been demonstrated from UK, USA, Canadian and
Japanese healthcare payer perspectives [10-13]. Cost-
effectiveness of LC in second line treatment after CB
has also been evaluated in predialysis from a UK
perspective [14].
The aim of this study was to evaluate the cost-
effectiveness of the use of LC as second line treatment in
CKD patients in a Spanish healthcare context, irrespective
of dialysis status, compared to a strategy of continued CB
(calcium carbonate and calcium acetate) treatment.
Methods
Model description
A decision analytic model and Markov modeling tech-
niques previously designed [14] were used to simulate the
progression of a hypothetical cohort of 1,000 Spanish
patients who are initially not on dialysis, representing the
relevant stages of the natural history of the disease over
time, as well as estimates for probability of progression
Table 1 Model inputs
Predialysis value (95% CI) Dialysis value (95% CI)
Average patient age 60 years
Gender 60% male
Renal disease origin 20% diabetes, 17% hypertension/renal vascular disease, 15% glomerulonephritis, 48% other cause
Target SP levels <4.6 mg/dL [3]
Initiation SP levels >4.6 mg/dL [19] >5.5 mg/dL [20]
Drug efficacy
Response rate to CB 44.5% (32.1-57.1) [21] 34.1%(31.0-37.4) [22]
Response rate to LC 38.3% (32.7-44.0) [19] 16.6% (13.5-19.9) [22]
Drug dosage
CC 3,000 mg/day 1,500 mg/day
CA 5,000 mg/day 3,000 mg/day
LC 1,875 mg/day 2,250 mg/day
Baseline yearly mortality 12.3% [16]
CKD baseline yearly progression 14.3% (13.6-15.0) [19]
RR of mortality by SP level For SA only
<2.5 mg/dL 0.95 (0.69-1.32) [17] 1.00 (0.96-1.24) [18] 1.00 (0.87-1.15)
2.5 mg/dL-3.0 mg/dL 1.00 (1.00-1.00) [17] 1.00 (0.96-1.24) [18] 1.00 (0.87-1.15)
3.0 mg/dL-3.5 mg/dL 1.15 (0.95-1.39) [17] 1.00 (0.93-1.07) [18] 1.00 (0.87-1.15)
3.5 mg/dL-4.0 mg/dL 1.32 (1.09-1.61) [17] 1.00 (0.93-1.07) [18] 1.00 (0.87-1.15)
4.0 mg/dL-4.5 mg/dL 1.34 (1.05-1.71) [17] 1.00 (1.00-1.00) [18] 1.00 (0.87-1.15)
4.5 mg/dL-5.0 mg/dL 1.83 (1.33-2.51) [17] 1.00 (1.00-1.00) [18] 1.00 (1.00-1.00)
5.0 mg/dL-5.5 mg/dL 1.90 (1.30-2.79) [17] 1.07 (1.01-1.14) [18] 1.00 (1.00-1.00)
5.5 mg/dL-6.0 mg/dL 1.90 (1.10-1.29) [17] 1.07 (1.01-1.14) [18] 1.02 (0.89-1.17)‡
6.0 mg/dL-7.0 mg/dL 1.90 (1.10-1.29) [17] 1.25 (1.17-1.34) [18]
7.0 mg/dL-8.0 mg/dL 1.90 (1.10-1.29) [17] 1.43 (1.31-1.54) [18] 1.18 (1.02-1.36)¥
8.0 mg/dL-9.0 mg/dL 1.90 (1.10-1.29) [17] 1.67 (1.51-1.86) [18] 1.39 (1.21-1.60)
>9.0 mg/dL 1.90 (1.10-1.29) [17] 2.02 (1.76-2.27) [18] 1.39 (1.21-1.60)
Utilities
Disease stage utility 0.71 [24] 0.61 [24]
CA: calcium acetate; CC: calcium carbonate; CKD: Chronic Kidney Disease; CI: confidence interval; LC: lanthanum carbonate; RR: relative risk; SA: Sensitivity
analysis; SP: Serum phosphorus.
‡from 5.5 mg/dL – 6.5 mg/dL.
¥from 6.6 mg/dL – 7.8 mg/dL.
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between the health states related to CKD. All parameters
of the model are summarized in Table 1.
A initial decision tree with clinical pathways was used to
identify subgroups of populations for further Markov
model simulation (Figure 1). The three health states con-
sidered in the Markov model were: predialysis, dialysis
and death. Patients were not allowed to transition from
the ‘dialysis’ to ‘predialysis state’ (Figure 1). The duration
of Markov cycles was established in one year, each patient
remained at least one year in each condition. A half-cycle
correction for outcomes and costs was applied to correct
the fact that patients may progress to a different health
state at any point during the one-year cycle [15].
Mortality and progression rates
High SP levels are associated with mortality risk in both stage
of disease (predialysis or dialysis), independent of renal func-
tion. Mortality rate for predialysis patients was estimated on
12.3% [16] adjusted with the relative risk related to SP levels
[17]. Mortality rate for dialysis population was estimated
from ERA-EDTA Annual Report and adjusted with SP levels
[18]. Calcium binders efficacy is indirectly related to mortal-
ity rate as they are expected to control SP and reduce the
associated of mortality [18]. CKD baseline progression rate
included in this model was 14.3% per year [19]. Relative Risk
of CKD progression was estimated to be 1.19 (1.10-1.29) per
1 g/dL of SP levels increase [19].
Cost-effectiveness analysis
The model predicted the clinical benefits in dialysis free
years and quality adjusted life years (QALY), and the
associated costs with each intervention, providing the in-
cremental cost-effectiveness ratio (ICER) of LC versus CB.
Populations and strategies assessed
Two CKD populations (predialysis and dialysis) were con-
sidered to assess the cost-effectiveness of second-line LC
treatment in patients previously treated with CB (calcium
carbonate or calcium acetate) compared with the contin-
ued use of CB regardless of treatment response.
Strategy 1 was CB continued therapy regardless the
treatment response for the whole cohort. Strategy 2
consisted on first-line treatment with CB, followed by a
LC second-line for those patients identified as non-
responders to CB in the decision tree.
Choice of second-line LC therapy initiation was modelled
according to K/DOQI guidelines and panel expert opinion.
Non-dialyzed patients with SP levels exceeding 5.5 mg/dL
were treated in second line with LC [20]. Dialyzed patients
non-responders to CB, started treatment with LC when SP
exceeded 4,6 mg/dL [21]. Patients not achieving target SP
with LC treatment after 8 weeks were switched back to CB.
The model considered a SP target level of ≤4.6 mg/dL for
predialyzed patients [3] and for dialyzed patients, based on
the recommendations from an expert panel consulted,
which was constituted by three Spanish nephrologists
specialized in dialysis management.
Clinical efficacy
Efficacy data of LC and CB were obtained from randomized
clinical trials (Table 1). For predialysis patients, efficacy was
based on pooled patient level data of predialysis and
Figure 1 Decision analytical structure and Markov mode. CB: calcium-based binder; LC: lanthanum carbonate.
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dialyzed patients due to low number of predialysis patients
treated with LC. LC efficacy data in predialysis patients was
taken from Sprague’s et al., a placebo-controlled study in
dialysis, resulting in a SP reduction from baseline levels
with LC (0.55 mg/dL vs 0.18 mg/dL with placebo, p = 0.02
for differences between groups) [20]. Only dialyzed patients
(stage 3 and 4) with SP predialysis baseline values were
included in order to increase homogeneity (n = 56 treated
with LC). CB efficacy in predialysis was taken from a ran-
domized controlled trial conducted in Spain, which com-
pared Calcium carbonate with Calcium acetate efficacy in
28 predialysis patients during a time period of 24 months
[22]. Patients baseline characteristics from both studies
were comparable: SP levels 5.7 ± 1.3 mg/dL [22] vs 5.5 ±
1.0 mg/dL [20] (p = 0.37), age 59.0 ± 15.3 years [22] vs 61.8
± 12.9 years [20] (p = 0.38) and glomerular filtration rate
20.5 ± 12.5 ml/min [22] versus 22.7 ± 6.7 ml/min [20] (p =
0.30). Efficacy data for CB and LC in dialyzed patients were
based on a Phase III, randomized, active comparator-
controlled trial evaluating the efficacy and safety of LC (n =
257 patients) versus calcium carbonate (n = 123) in CKD
patients over a time period of 6 months [23]. The mean age
of this population was 57 years (LC) and 58.4 years (calcium
carbonate). On average, patients had received hemodialysis
for 42.9 months (LC) and 43.8 months (calcium carbonate).
The percentage of patients with residual renal function was
65.2% (LC) and 63.6% (calcium carbonate). Only patients
with SP levels >5.58 mg/dL were randomized.
Long term efficacy was assumed as similar for predia-
lysis and dialysis patients treated with LC and CB.
Following current guidelines recommendations, target
SP level for predialysis [3], in the model were <4.6 mg/
dL. The clinical expert panel advised to consider the
same target SP for the dialyzed patients.
Utilities and adverse events
Quality of life (QoL) estimates were based on a published
systematic review [24]. The results were averaged to result
in utility estimate of 0.71 and 0.61 for predialysis and dia-
lyzed patients. Data from clinical trials used to obtain effi-
cacy data demonstrated that LC was associated to less
adverse events rates than the comparator (47.4% vs 61.0%
with placebo [20], or 77.7% vs 79.8% with calcium acetate
[23]). However vomiting seemed to be associated with sig-
nificantly increased rate in LC arm in predialysis patients
(4.0%) [20], and dialysis patients (7.2%) [23], so it was de-
cided to test influence of the potential affectation in patient
QoL. Based on a published study, the model considered a
utility decrement of 0.04082 for each vomiting episode [25].
Perspective, time horizon, and discount rate
The analysis was performed for a Spanish public health
care system perspective. Lifetime horizon (40 years
maximum) was adopted for base case following all
patients until death, applying a 3% annual discount rate
for both, costs and health benefits, according to the last
published recommendations [26].
Costs
Based on the perspective, only direct health cost were
included. All costs were expressed in euros (€), 2013 year
value (Table 2).
Daily Drug Doses (DDD) were based on expert panel
recommendations. Drug costs were obtained from the
Spanish General Council of Official Pharmaceutical
Colleges catalogue [27]. Ex-factory prices adjusted with
7.5% mandatory deduction [28,29] were used. Annual
costs for a dialyzed patient were estimated on €42,555.6
based on Ministry of Health estimations from a national














Fosrenol® 750 mg 90 chewable tablets €167.86 €2.48 €1,702 €2,042
Calcium binders (average CC, CA) [27] €49 €93
Calcium carbonate (CC)
Mastical® 1,250 mg 60 chewable tablets €2.09 €0.027 €30 €50
90 chewable tablets €2.97
Calcium acetate (CA)
Royen® 1,250 mg 60 chewable tablets €7.13 €0.124 €68 €136
120 chewable tablets €3.91
Dialysis costs [28] €42,556
CA: Calcium Acetate; CC: Calcium Carbonate.
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health database [30]. No additional cost was considered
for managing adverse effects (vomits). Prolonged dialysis
care is related to the extended life of treated patients ra-
ther than to phosphate binder choice [31,32]. Dialysis
costs in the added life years were classified as unrelated
future costs and in line with previous cost-effectiveness
analysis [14] were not included in the base case, but ex-
plored in sensitivity analysis.
Sensitivity analysis
One-way and probabilistic sensitivity analysis were
performed to test the robustness of the model and to de-
termine the impact of uncertainty on the incremental
cost-effectiveness ratio. The following parameters were
varied: inclusion of unrelated future costs (long term
dialysis costs), comparator (calcium carbonate only or
calcium acetate only), time horizon (5 and 10 years
horizon) and discount rate (0% and 6%)
Probabilistic analysis by a Montecarlo simulation was
performed varying simultaneously the values for input pa-
rameters with a specific probability distribution for each
of the parameters of interest. This process was repeated
1,000 times to provide a distribution of the model results.
Costs and dose equivalence ratios were assumed to be log-
normal distributed, binomial distributions were adopted
for treatment response probabilities, normal distributions
for relative risks and mortality rate of dialysis patients and
beta distributions for health related utilities.
Results
Over a lifetime horizon, LC achieved 4.653 QALYs per
treated patient. With CB 4.579 QALYs were gained.
Drug costs for LC therapy were €1,169, whereas for CB
they were €468. The additional SP lowering effects of LC
delayed CKD progression in LC responders, resulting in
108 dialysis free years gained. These dialysis free years
resulted in large health care cost benefits because of the
decrease of the dialysis costs with CB estimated in
€4,576. Difference on lifetime total costs were € -3,875
for LC versus CB.
Second-line LC was associated with higher health
benefits and also with costs savings, and therefore
was identified as a dominant strategy over continuous
CB treatment. The estimated costs and clinical bene-
fits of the use of LC as second line therapy after ther-
apy failure with CB in predialysis and dialysis patients
to prevent CKD progression and mortality are shown
on Table 3.
One-way sensitivity analysis results confirmed model
and parameters robustness as LC continued being a
dominant strategy in all the analysis performed (Table 4),
apart from the inclusion of unrelated future dialysis
costs, which provided an ICER of €45,554 per QALY
gained. Although no specific threshold is officially estab-
lished in Spain, this value is around one of the commonly
accepted threshold of €45,000/QALYgained proposed by
other authors for Spain [33].
Table 3 Cost-effectiveness results (cohort of 1,000 patients)
Continuous CB Second line LC Difference
Therapy response
Number of responders in
predialysis
445 658 213
Number of responders in dialysis −60 −57 3
Total number of responders 385 601 216
Health outcomes
Life Years 6,868 6,981 113
Dialysis free years 0 108 108
QALY’s 4,579 4,653 74
Costs –(€, 2013)
Total costs (€ thousand) €5,044 €1,169 € -3,875
Drug costs (€ thousand) €468 €1,169 € 701
Dialysis costs (€ thousand) €4,576 €0
Cost-effectiveness incremental ratio (ICER)
Cost per life-year gained (€) Dominant
Cost per QALY gained (€) Dominant
Net monetary benefit (€ thousand) €6,092
CA: Calcium Acetate; CB: Calcium Binder; CC: Calcium Carbonate; ICER: Incremental cost-effectiveness ratio; LC: Lanthanum Carbonate; QALY: Quality Adjusted
Life Year.
Detailed results in terms of total costs and health benefits obtained for 1,000 patients followed lifetime, with each of the comparators are shown. Differences
between therapeutic alternatives were calculated to estimate ICER. LC resulted a dominant strategy (more efficacious and less costly) compared to CB.
Gros et al. Health Economics Review  (2015) 5:14 Page 5 of 9
Time horizon was a parameter with great influence on
results. Time horizon shortening had a positive effect on
ICER, being the analysis with the shortest time horizon
(5 years) the one with the lowest ICER. Figure 2 shown
results of 1,000 interactions, performed on probabilistic
sensitivity analysis, plotted on a cost-effectiveness plane.
LC resulted a dominant option in 99.6% of the simula-
tions. Assuming either a €45,000/QALY gained threshold
[33] or an alternative €30,000/life year gained threshold
[34], LC compared to CB would be a cost-effective strat-
egy as second line treatment in 100% of simulations.
Discussion
The dose of CB in CKD disease patients with hyperpho-
sphatemia has been related with the severity of arterial
calcification and death in these patients [35]. High cal-
cium levels also stimulate the induction of a hypercoagu-
lability site directly related to an increase in
cardiovascular mortality risk [36-38] .
Although its relation with hypercalcemia, CB prescrip-
tion in Spain has increased over recent years due to its
lower price and the current healthcare budget restric-
tions in Spain [39].
Table 4 One-way sensitivity analysis
Continuous CB Second line LC Difference ICER (€/QALY gained)
BASE CASE
QALYs 4,579 4,653 73.88 Dominant
Costs (thousands) €5,044 1,169 - €3,875
SA1 Time horizon (5 years)
QALYs 2,555 2,580 25.50 Dominant
Costs (€ thousand) €2,452 €835 - €1,616
SA2 Time horizon (10 years)
QALYs 3,711 3,760 48.67 Dominant
Costs (€ thousand) €3,920 €1,028 - €2,892
SA3 Included unrelated future dialysis costs
QALYs 4,579 4,653 73.88 €45,557
Costs (€ thousand) €127,149 €130,515 €3,336
SA4 Dialysis target level 5 mg/dL
QALYs 4,579 4,658 79.30 Dominant
Costs (€ thousand) €5,044 €1,383 - €3,661
S5 Annual Discount Rate (6%)
QALYs 3,846 3,903 56.95 Dominant
Costs (€ thousand) €4,122 €1,036 - €3,086
S6 Annual Discount Rate (0%)
QALYs 5,598 5,498 99.48 Dominant
Costs (€ thousand) €6,346 €1,348 - €4,999
S7 Only considering Acetate carbonate
QALYs 4,643 4,713 69.54 Dominant
Costs (€ thousand) €4,906 €1,324 - €3,582
S8 Only considering Calcium carbonate
QALYs 4,511 4,590 79.02 Dominant
Costs (€ thousand) €5,223 €1,025 - €4,198
S9 Dialysis mortality from Block 1998
QALYs 4,571 4,620 49.51 Dominant
Costs (€ thousand) €4,840 €1,170 -€3,670
S10 Without utility decrement for vomiting
QALYs 4,579 4,653 73.93 Dominant
Costs (€ thousand) €5,044 1,169 - €3,875
CA: calcium acetate; CB: Calcium Binder; CC: calcium carbonate; ICER: Incremental cost-effectiveness ratio; LC: lanthanum carbonate; QALY: Quality Adjusted
Life Year.
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Recent studies have suggested that LC treatment was as-
sociated with the reduced progression of aortic calcification
in dialyzed patients [9]. However, additional clinical studies
involving larger sample sizes and long-term follow-up are
required to confirm this fact, and to rule out the possibility
that the continuous LC administration might be generate
any adverse events.
However, studies have demonstrated that prevention
and delaying of end stage kidney disease lead to not
only clinical benefits but also important cost savings
because dialysis cost are high [40,41]. In addition, the
cost-effectiveness of dialysis process has already been
contested [42].
Despite of the great differences on pharmaceutical
costs between LC and CB, in the present economic
evaluation, second-line treatment with LC resulted a
dominant option over CB therapy. The inclusion of un-
related future dialysis costs was associated with higher
drug costs over a patient’s lifetime horizon than CB
treatment, but the estimated ICER (€45,557/QALY) was
just around one of the commonly accepted Spanish
threshold (willingness to pay) [33]. Caution is necessary
in comparing results with other economic evaluations
due to differences in methods, setting and input parame-
ters, as well as to differences in the alternatives used in
the evaluations. However, the original model structure
performed was used to perform an assessment of LC cost-
effectiveness from a UK healthcare perspective [14] and
also concluded that LC was a cost-effective strategy com-
pared to CB therapy for the treatment of hyperpho-
sphatemia, after failure of a CB first-line treatment.
Some limitations should be taken into account when
interpreting findings derived from the present analysis.
The most important were related to the limited efficacy
data in predialysis patients and the potential uncertainty
associated. However, this has already been widely dis-
cussed in the previous publication using the same model
for UK setting [14].
Due to the lack of studies, epidemiological data related
to mortality and CKD progression have been considered
from studies conducted in other countries other than
Spain. Nevertheless, based on their experience and
knowledge the expert panel considered that these data
were representative for the Spanish population.
QoL is highly related to social preferences. The utilities
values used in the present model derived from a system-
atic review in CKD population [24] which assessed studies
on different settings and countries. No study specifically
referring to a Spanish population with CKD was found by
authors, so international values were applied, based on the
assumption that the sources used were representative of
the Spanish population as they have been taken from
European publications. Similarly, the utility decrement
due to vomiting as an adverse event related to LC was
based on a study on non-small lung cancer [25], because
specific data in populations with renal disease were un-
available. Furthermore, the influence of these parameters
on the cost-effectiveness outcomes was small. Influence of
adverse events other than vomiting was not tested. Avail-
able evidence about safety profile of LC [9,23] suggested an
equivalent or higher tolerability than CB, so the results
shown could be considered underestimating the total cost
of CB.
Although they have been widely demonstrated [5], the
potential deleterious effects of CB were not modelled.
The expert panel considered that against recommenda-
tions for hyperphosphatemia treatment of current clin-
ical guidelines in Spain, CB are not always prescribed in
clinical practice as first treatment option, due to these
negative effects.
Figure 2 Cost-effectiveness plane. QALY: Quality Adjusted Life Year. The cost-effectiveness plane is the most common representation of the
results of cost-effectiveness analysis results. The origin represents the standard alternative (calcium binders). Each point represents the ICER of
each one of the 1,000 simulations conducted comparing the new alternative (LC) versus the standard one (CB). Most of the ICERs of LC versus
CB resulted in lower costs and higher effectiveness, so points fell in the second quadrant, LC being classified as dominant option.
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Pill burden reduction associated to LC therapy com-
pared to CB could improve adherence and therapy
compliance [14]. CKD lack of adherence to treatment
in Spain has been highlighted by an important obser-
vational study of 121 hemodialysis patients [43]. The
lack of adherence to treatment not only prevents the
achievement of control targets but may additionally
represent a financial burden to the health system and
pose a major obstacle to effective treatment [44] In
this sense, LC oral powder has already demonstrated
its efficacy, and its positive effect on adherence to
treatment in CKD patients [45].
However, due to the lack of information along with
the difficulties to quantify adherence, influence of pill
burden on QoL or drug efficacy was not included in the
model representing a conservative approach for LC,
because increase on patients QoL could be potentially
derived from its inclusion. Further investigations on the
LC pill burden reduction effect will be interesting to be
considered in future economic evaluations as better
adherence would be expected to impact positively on
improved efficacy.
The inclusion or exclusion of unrelated future costs is the
topic of a long-standing and as-of-yet unresolved discus-
sion. Unrelated future costs were excluded from the base-
case of the present analysis but tested on sensitivity analysis.
This demonstrated a sizeable influence on the cost-
effectiveness results although the inclusion of these costs is
an area of important debate in economic evaluations [46].
Although the present results could not be considered as
definitive due to the limitations mentioned, they could
provide useful information for clinicians and decision
makers. Overall, we attempted to use conservative as-
sumptions and approaches for each of the limitations
mentioned, therefore findings provided by the present
model can be considered as conservative. It would be
interesting to confirm preliminary results in further evalu-
ations, but many times it is not feasible, so this analyses
aimed to increase the scientific knowledge and any effort
on this way must be welcomed, meanwhile the lack of reli-
able local data avoids a model update.
Results from cost-effectiveness studies along with
the higher mortality rate and higher costs (related to
dialysis) associated to CB, have also to be taken into
account not only by clinicians but also by decision
makers in order to protect the National Health Service.
Conclusions
The findings of the present model suggested that in Spain
LC therapy for second line treatment of hyperphosphatemia
in CKD patients was a dominant strategy compared to con-
tinuous CB treatment. This important finding should be
taken into account when choosing a phosphate binder
treatment for hyperphosphatemia associated to CKD.
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